Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Osteoporosis is a systemic skeletal disease responsible for the high incidence of fractures in older subjects, particularly in postmenopausal women. The increasing prevalence with population ageing and prolonged life expectancy raises the rates of associated morbidity, loss of independence, and mortality. BMD and previous fracture history are two main risk factors associated with osteoporosis such that the presence of prior fractures can predict future fractures. Strontium ranelate is an agent developed for the management of postmenopausal osteoporosis, demonstrated to reduce vertebral, nonvertebral, major nonvertebral, and hip fractures. It has been demonstrated to be effective for a broad spectrum of patients, including women with osteopenia, osteoporosis, and severe disease.

Original publication

DOI

10.1007/s00198-010-1251-0

Type

Journal article

Journal

Osteoporos int

Publication Date

06/2010

Volume

21 Suppl 2

Pages

S425 - S429

Keywords

Aged, Bone Density Conservation Agents, Female, Humans, Male, Middle Aged, Osteoporosis, Osteoporotic Fractures, Risk Assessment, Strontium Radioisotopes